Subscribe To
KYMR / Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
![Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner](https://cdn.snapi.dev/images/v1/z/p/default27-2111679.jpg)
KYMR News
![Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/w/e/transcript33-2140566.jpg)
By Seeking Alpha
November 4, 2023
Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, I more_horizontal
![Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner](https://cdn.snapi.dev/images/v1/z/p/default27-2111679.jpg)
By Zacks Investment Research
October 19, 2023
Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Kymera Therapeutics, Inc. (KYMR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong more_horizontal
![Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner](https://cdn.snapi.dev/images/v1/m/m/default11-2109280.jpg)
By Zacks Investment Research
October 18, 2023
Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Kymera Therapeutics, Inc. (KYMR) as it is technically in oversold territory now. In addition to th more_horizontal
![Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock? Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?](https://cdn.snapi.dev/images/v1/b/q/default297-2089138.jpg)
By Zacks Investment Research
October 4, 2023
Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?
Kymera Therapeutics, Inc. (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings more_horizontal
![Why Shares of Kymera Therapeutics Jumped on Tuesday Why Shares of Kymera Therapeutics Jumped on Tuesday](https://cdn.snapi.dev/images/v1/0/t/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f7497262fdoctors-white-coat-healthcare-1jpgopresizew400h400-2088622.jpg)
By The Motley Fool
October 3, 2023
Why Shares of Kymera Therapeutics Jumped on Tuesday
Kymera Therapeutics has nine programs in its pipeline. It has a collaboration with Sanofi on its lead therapy IRAK-4. more_horizontal
![Kymera Therapeutics - Need More Developments Before Making This A Buy Kymera Therapeutics - Need More Developments Before Making This A Buy](https://cdn.snapi.dev/images/v1/3/l/image-1152347310-2015800.jpg)
By Seeking Alpha
August 9, 2023
Kymera Therapeutics - Need More Developments Before Making This A Buy
Kymera Therapeutics' valuation is difficult to estimate due to lack of positive net income, making it a poor buy. The company received FDA Orphan Drug more_horizontal
![Perella Weinberg Partners (PWP) Q2 2023 Earnings Call Transcript Perella Weinberg Partners (PWP) Q2 2023 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/x/n/transcript13-2008851.jpg)
By Seeking Alpha
August 6, 2023
Perella Weinberg Partners (PWP) Q2 2023 Earnings Call Transcript
Perella Weinberg Partners (PWP) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants Bruce Jacobs - CFO Nello Mainolfi - Fo more_horizontal
![Kymera: More Data Needed Kymera: More Data Needed](https://cdn.snapi.dev/images/v1/t/g/image-1281026029-1889129.jpg)
By Seeking Alpha
May 14, 2023
Kymera: More Data Needed
Kymera produced solid-looking phase 1 data, but Pfizer's problems in the space, along with some safety issues, hurt its stock. When partner Sanofi pro more_horizontal